LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-19
Case ID: NM_004364.3_c.576G_T_20261119_141539
Framework: ACMG/AMP 2015
Variant classification summary

NM_004364.3:c.576G>T

CEBPA  · NP_004355.2:p.(Pro192=)  · NM_004364.3
GRCh37: chr19:33792745 C>A  ·  GRCh38: chr19:33301839 C>A
Gene: CEBPA Transcript: NM_004364.3
Final call
VUS
PM2 moderate BP4 supporting
All criteria require review: For research and educational purposes only.
Gene
CEBPA
Transcript
NM_004364.3
Protein
NP_004355.2:p.(Pro192=)
gnomAD AF
3.876660179721966e-06 (v4.1)
ClinVar
Likely benign
OncoKB
Unknown Oncogenic Effect
Interpretation summary
Generated evidence synthesis
1
PM2 moderate: gnomAD v4.1 grpmax FAF is 0.003892%, below the 0.01% cutoff.
2
BP4 supporting: SpliceAI maximum delta 0.003 is below the 0.1 no-impact threshold.
Final determination: Under generic ACMG/AMP 2015 rules, one Moderate criterion and one Supporting criterion do not satisfy any pathogenic or benign combination, so the final call is VUS.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a synonymous variant.
pvs1_generic_framework generic_acmg_combination_rules
PS1 N/A Not applicable: PS1 requires a missense variant, and this is a synonymous variant.
generic_acmg_combination_rules
PS2 Not assessed Not assessed: no documented affected proband, family-history status, or confirmed maternity and paternity is available for this variant.
PS3 Not assessed Not assessed: no variant-specific functional assay was identified, and the only quantitative result was computational SpliceAI prediction (maximum delta score 0.003).
generic_acmg_combination_rules PMID:25741868 PMID:31189880
PS4 Not assessed Not assessed: no affected-case and control counts, odds ratio, or confidence interval are available to evaluate the PS4 >5.0 and CI-not-including-1.0 requirements.
PMID:24121147 gnomad_v4
PM1 N/A Not applicable: PM1 requires a missense variant, and this is a synonymous variant.
generic_acmg_combination_rules
PM2 Met Met at Moderate: gnomAD v4.1 grpmax FAF is 0.003892%, below the 0.01% PM2 cutoff, with five alleles and no homozygotes; gnomAD v2.1 is absent.
gnomad_v2 gnomad_v4 PMID:25741868
PM3 N/A Not applicable: CEBPA familial acute myeloid leukemia is described as autosomal dominant, whereas PM3 is restricted to recessive disorders with confirmed trans phase.
PM4 N/A Not applicable: PM4 requires a protein-length change, and this is a synonymous variant.
pvs1_generic_framework generic_acmg_combination_rules
PM5 N/A Not applicable: PM5 requires a missense variant, and this is a synonymous variant.
generic_acmg_combination_rules
PM6 Not assessed Not assessed: no assumed de novo occurrence or parental testing information is documented for this variant.
PP1 Not assessed Not assessed: no affected relatives, genotypes, or segregation data are documented for this variant.
PP2 N/A Not applicable: PP2 requires a missense variant, and this is a synonymous variant.
generic_acmg_combination_rules
PP3 Not met Not met: synonymous-variant SpliceAI max delta 0.003 is below the PP3 threshold of >=0.2.
spliceai PMID:25741868
PP4 Not assessed Not assessed: no patient phenotype or family history is available that demonstrates high specificity for a disease with a single genetic etiology.
PP5 Not met Not met: ClinVar has 0 expert-panel submissions, and its non-expert Likely benign assertions cannot trigger PP5.
clinvar
BA1 Not met Not met: gnomAD v4.1 grpmax FAF is 0.003892%, far below the 5% BA1 threshold, despite a South Asian point estimate of 0.01003%.
gnomad_v4 gnomad_v2
BS1 Not met Not met: gnomAD v4.1 grpmax FAF is 0.003892%, below the generic 1% BS1 threshold and therefore does not indicate an excessive disease frequency.
gnomad_v4 PMID:28518168
BS2 N/A Not applicable: BS2 requires an early-onset, fully penetrant disorder, whereas CEBPA-associated AML has age-dependent penetrance and no exact-variant healthy-adult assessment is documented.
gnomad_v4
BS3 Not assessed Not assessed: no validated experimental evidence shows that CEBPA c.576G>T preserves protein function or splicing; SpliceAI is computational only.
generic_acmg_combination_rules PMID:25741868 PMID:31189880
BS4 Not assessed Not assessed: no tested affected relatives lacking the variant are documented, so non-segregation cannot be evaluated.
BP1 N/A Not applicable: BP1 requires a missense variant, and this is a synonymous variant.
generic_acmg_combination_rules
BP2 Not assessed Not assessed: no documented cis/trans phase result or pathogenic partner variant is available for this synonymous CEBPA variant.
BP3 N/A Not applicable: BP3 requires an in-frame indel in a repeat region, and this is a synonymous variant.
pvs1_generic_framework generic_acmg_combination_rules
BP4 Met Met at supporting: synonymous-variant SpliceAI max delta 0.003 meets the BP4 threshold of <=0.1.
spliceai PMID:25741868
BP5 Not assessed Not assessed: no case documents this variant together with a confirmed alternate molecular basis for the relevant disease.
BP6 Not met Not met: ClinVar has 0 expert-panel submissions, so its non-expert Likely benign classifications cannot trigger BP6.
clinvar
BP7 Not assessed Not assessed: SpliceAI max delta 0.003 supports no splice impact, but BP7's required nucleotide-conservation assessment is unavailable.
spliceai PMID:25741868
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.